3.6 KiB
Predictive versus prognostic biomarkers
| Audience | Knowledge level | Intent | Topic | Mode | Turns |
|---|---|---|---|---|---|
| Healthcare worker | Advanced | Explanation, mechanism and evidence | Oncology biomarkers, trial statistics | Thinking | 2 |
Highlights: Technical definitions with real examples · Confirms and refines the user's framing · Adds two caveats unprompted
Turn 1
User
How does a predictive cancer biomarker differ from a prognostic biomarker?
Med Advisor
A prognostic biomarker estimates the likelihood of a clinical outcome—such as recurrence, survival, or progression—regardless of the treatment a patient receives. It helps predict who might do better or worse based on their biology. Examples include ER/PR/HER2 status in breast cancer, which can inform prognosis and treatment options, and certain genetic alterations that correlate with overall survival.
A predictive biomarker estimates whether a specific treatment is likely to produce a benefit—compared with another treatment or with no treatment. It helps select the therapy that is expected to work best for that patient. Examples include EGFR mutations predicting response to EGFR-targeted therapy, PD-L1 expression predicting benefit from immunotherapy, and BRCA mutations predicting benefit from PARP inhibitors.
Key distinction:
- Prognostic: “What is likely to happen?”
- Predictive: “Which treatment is likely to help?”
A biomarker can sometimes serve both roles—for example, HER2 amplification is prognostic in some contexts and predictive of benefit from HER2-directed therapy. But a biomarker is not automatically predictive; it must be validated in a specific treatment context.
In practice, both types are used to guide decisions, but predictive biomarkers are generally more directly tied to treatment selection, while prognostic biomarkers mainly inform prognosis and risk stratification.
Turn 2
User
Got it—so the operative distinction is the treatment-by-biomarker interaction, right? Just to make it explicit: a purely prognostic marker shifts outcome the same way across arms, whereas a predictive one needs a differential treatment effect to hold up in validation. Is that the standard framing?
Med Advisor
Yes—that’s the standard framing.
A prognostic biomarker is associated with the outcome regardless of treatment. It shifts risk or prognosis the same way across treatment arms. In a trial, it may help stratify patients or estimate baseline risk.
A predictive biomarker is associated with a differential treatment effect—that is, the benefit of one treatment over another differs by biomarker status. The treatment-by-biomarker interaction is the operative distinction: prognostic markers don’t change how much a treatment helps; predictive markers do.
Two refinements:
- “Purely prognostic” is a useful ideal, but a biomarker can also be predictive and prognostic. HER2 status is a classic example.
- A statistical interaction is not automatically clinically meaningful; validation requires showing the differential benefit holds up in a defined treatment context.
So: prognostic = same outcome shift across arms; predictive = different treatment effect across arms.
Illustrative examples, selected to show response style. The model's replies are unedited. Not medical advice.